HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Read this article in Polish Commentary from Polish edition Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montané, E. Articles by Laporte, J. R. Search for Related Content PubMed PubMed Citation Articles by Montané, E. Articles by Laporte, J. R. Related Collections Spastic paraplegia All Clinical trials

Oral antispastic drugs in nonprogressive neurologic diseases

A systematic review

From Unitat d’Assaigs Clínics i Farmacoepidemiologia (Drs. Montané and Laporte), Fundació Institut Català de Farmacologia (Drs. Montané, Vallano, and Laporte), Servei de Farmacologia Clínica, Hospital Universitari Vall d’Hebron (Drs. Vallano and Laporte), and Universitat Autònoma de Barcelona (Drs. Montané, Vallano, and Laporte), Barcelona, Spain.

Address correspondence and reprint requests to Dr. Eva Montané, Servei de Farmacologia Clínica, Pg Vall d’Hebron, n° 119-129, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain; e-mail: eme{at}icf.uab.es

Objective: To assess the efficacy of oral drugs in the treatment of spasticity in patients with nonprogressive neurologic disease (NPND).

Methods: Systematic review of double-blind randomized controlled trials of antispastic oral drugs in the treatment of spasticity in NPND. Data sources: Electronic MEDLINE, PubMed, Cochrane Library, and hand searches.

Results: Twelve studies (469 patients) were included (6 on stroke, 3 on spinal cord diseases, and 3 on cerebral palsy). Tizanidine was assessed in four trials (276 patients, 142 exposed), dantrolene in four (103, 93), baclofen in three (70, 55), diazepam in two (127, 76), and gabapentin in one (28, all exposed). Most trials were of small size, of short duration, and their methodologic quality was inadequate. Ten trials were controlled with placebo and only two were direct comparisons between drugs. Efficacy outcome variables were heterogeneous. Only four reports described the magnitude of the antispastic effect. The incidence of adverse drug effects (drowsiness, sedation, and muscle weakness) was high.

Conclusion: Evidence on the efficacy of oral antispastic drugs in NPND is weak and does not include evaluation of patients’ quality of life. If any, efficacy is marginal. Adverse drug reactions were common. Better methodologic instruments are needed for the evaluation of antispastic treatment.

Received March 23, 2004. Accepted in final form May 28, 2004.

This article has been cited by other articles:

				D. L. Hurst, W. A. Lajara-Nanson, and M. E. Lance-Fish Walking With Modafinil and Its Use in Diplegic Cerebral Palsy: Retrospective Review J Child Neurol, April 1, 2006; 21(4): 294 - 298. [Abstract] [PDF]

				W. M. Landau, E. Montane, A. Vallano, and J.-R. Laporte Oral antispastic drugs in nonprogressive neurologic diseases: A systematic review Neurology, June 14, 2005; 64(11): 1989 - 1990. [Full Text] [PDF]

				Are Oral Antispasticity Drugs Effective in Nonprogressive Neurologic Diseases? Journal Watch Neurology, February 11, 2005; 2005(211): 5 - 5. [Full Text]

Correspondence: